Group 1 - Lichong Group expects a net profit of 830 million to 870 million yuan for 2025, representing a year-on-year growth of 17.38% to 23.04% [1] - Shandong Zhanggu anticipates a net profit of 72 million to 80 million yuan for 2025, with a year-on-year increase of 0.65% to 11.83% [2] - Yinglian Co. forecasts a net profit of 32 million to 42 million yuan for 2025, marking a turnaround from a loss of 39.67 million yuan in the previous year [3] Group 2 - Hangya Technology announces plans for shareholders to reduce their holdings by up to 2.76% of the company's shares [4] - Guizhou Tire plans to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [5] - Laisentongling's shareholder plans to reduce their stake by no more than 1% [6] Group 3 - ST Yifei's shareholder intends to reduce their holdings by up to 1.53% [7] - Hengyi Petrochemical has fully launched the second phase of its Brunei refining project, aiming for a production capacity of 12 million tons per year [8] - Zai Sheng Technology's controlling shareholder has terminated an agreement to transfer part of the company's shares [9] Group 4 - Sry New Materials proposes a cash dividend of 0.4 yuan per 10 shares for the first three quarters of 2025 [10] - Quanyin High-Tech announces that the offer period for China Seed Group's acquisition has expired, leading to a temporary suspension of its stock [11] - Zhonggang Luonai's shareholder plans to reduce their stake by up to 1% [12] Group 5 - Nanmo Bio expects to receive a government subsidy of 5.8 million yuan for its subsidiary [13] - Beite Technology has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [14] - Qianyuan Pharmaceutical's subsidiary has obtained drug registration certificates for a new medication [15] Group 6 - Boto Integrated plans to reduce its holdings by no more than 1% [16] - Wanze Co. intends to reduce its stake by up to 1.66% [17] - Tianci Materials will halt production for maintenance on its lithium hexafluorophosphate production line starting March 1, 2026 [18] Group 7 - Haopeng Technology plans to raise up to 800 million yuan through a private placement [20] - Yisheng Co. reports a 43.32% year-on-year increase in sales revenue for its white feather broiler chicks in December 2025 [21] - Jinyu Medical proposes a cash dividend of 8.8 yuan per 10 shares for the first three quarters of 2025 [22] Group 8 - Caesar Travel's subsidiary has won a management service project for the Qingdao International Cruise Port [23] - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan [24] - Jiangling Motors reports a 10.56% year-on-year increase in cumulative sales for 2025 [25] Group 9 - Yilian Technology plans to issue convertible bonds to raise up to 1.2 billion yuan [26] - Shaanxi Guotou A intends to participate in a capital increase for Chang'an Bank, with an amount not exceeding 800 million yuan [27] - Oupokang Vision has obtained a production license for eye drops [28] Group 10 - Shanghai Electric plans to provide management services for overseas assets of China Electric International [30] - Yingfang Micro is planning a major asset restructuring, leading to a temporary suspension of its stock [31] - Victory Energy's stock will resume trading after completing a verification process [32] Group 11 - China Merchants Industry has signed a shipbuilding agreement with Dalian Shipbuilding [33] - Kunyu Group has appointed a new chairman following a board meeting [34] - Microchip Bio's clinical trial application for a new diabetes treatment has been accepted [35] Group 12 - Hanshuo Technology has signed a sales intention agreement for smart shopping carts with Woolworths in Australia [36] - Zhongmin Energy's three photovoltaic power station projects have been included in the Fujian Province development list [37] - Penghui Energy plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [38] Group 13 - Victory Energy reports that the acquirer has deposited a guarantee for the acquisition [39] - Fangsheng Pharmaceutical proposes a special dividend of 0.15 yuan per share for 2025 [40] - Nanning Department Store has received approximately 14.28 million yuan in government subsidies since January 2025 [41] Group 14 - Jushen Co. has signed a bauxite transfer agreement with a company in Guinea [42] - ST Huluwawa has received a drug registration certificate for a new inhalation solution [43] - Zhongzhi Co. will become the controlling shareholder following a share transfer agreement [44] Group 15 - Chuangli Group has signed a strategic cooperation framework agreement with Chuanjiu Construction [45]

Core Viewpoint - The approval of the drug Eivocase tablets by the National Medical Products Administration is a significant milestone for Qianyuan Pharmaceutical, enhancing its product portfolio and market competitiveness, although future sales remain uncertain [1] Company Summary - Qianyuan Pharmaceutical's subsidiary, Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., received the drug registration certificate for Eivocase tablets [1] - Another subsidiary, Jiangsu Jiayi Pharmaceutical Co., Ltd., obtained the approval notice for the listing application of Eivocase as a chemical raw material drug [1] - Eivocase tablets are indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis and are classified as a Category B product in the national medical insurance catalog [1] Industry Summary - The approval of Eivocase tablets is expected to enrich the company's product structure and enhance its competitiveness in the pharmaceutical market [1] - The future sales performance of Eivocase tablets is subject to uncertainty, reflecting potential challenges in market acceptance and competition [1]

Core Viewpoint - Recently, Shaanxi Macao Medical Technology Co., Ltd. submitted an application for listing on the Hong Kong Stock Exchange, focusing on the development of next-generation bispecific/multispecific peptide drugs for metabolic diseases, particularly kidney-related and cardiovascular diseases [1][2]. Financial Performance - The company has no commercialized products, with revenue primarily from government subsidies and bank interest, reporting other income of 6.969 million, 4.002 million, and 1.222 million yuan for 2023, 2024, and the first half of 2025 respectively [2]. - The company incurred losses of 195 million, 157 million, and 49.9 million yuan during the same periods, totaling approximately 400 million yuan in losses over two and a half years, with R&D expenditures exceeding 200 million yuan [2]. - As of June 2025, the company had cash reserves of only 107 million yuan and net current liabilities of 907 million yuan, primarily due to redemption liabilities from pre-IPO financing [2]. Product Pipeline and Development - The company has made progress in its research pipeline, with FDA approval for clinical research of XTL6001 for obesity and weight management in 2024, and approval from the National Medical Products Administration for XTL6001 for proteinuric chronic kidney disease in 2025 [3]. - The company ranks first among domestic pharmaceutical companies in terms of the number of clinical-stage bispecific/multispecific peptide candidates, with over 30 new drug candidates, including 7 original innovative drug pipelines in clinical development [4]. Market Competition - The core product MT1013 is a globally pioneering dual-target receptor agonist peptide drug aimed at secondary hyperparathyroidism (SHPT), with expectations for commercialization in early 2028 [6]. - The competitive landscape includes Evocalcet, a new oral calcimimetic drug for SHPT, which has shown improvements in molecular structure and formulation processes, potentially increasing market competition for MT1013 [6][7]. IPO Significance - The IPO is crucial for the company to maintain R&D and normal operations, as it seeks to address its financial challenges and enhance investor confidence amid declining valuations from C to D round financing [2][3].